BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7911734)

  • 1. Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma.
    Roncalli M; Viale G; Grimelius L; Johansson H; Wilander E; Alfano RM; Springall D; Battezzati PM; Polak JM; Coggi G
    Cancer; 1994 Jul; 74(1):134-41. PubMed ID: 7911734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma.
    Viale G; Roncalli M; Grimelius L; Graziani D; Wilander E; Johansson H; Bergholm U; Coggi G
    Hum Pathol; 1995 Sep; 26(9):945-50. PubMed ID: 7672794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions.
    Komminoth P; Roth J; Saremaslani P; Matias-Guiu X; Wolfe HJ; Heitz PU
    Am J Surg Pathol; 1994 Apr; 18(4):399-411. PubMed ID: 8141431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of c-Myc, TGF-alpha and EGF-receptor in sporadic medullary thyroid carcinoma.
    Wang W; Johansson HE; Bergholm UI; Westermark KM; Grimelius LE
    Acta Oncol; 1997; 36(4):407-11. PubMed ID: 9247102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD15 (LeuM1) immunoreactivity: prognostic factor for sporadic and hereditary medullary thyroid cancer? Study Group on Multiple Endocrine Neoplasia of Austria.
    Längle F; Soliman T; Neuhold N; Widhalm G; Niederle B; Roka S; Kaserer K; Blauensteiner W; Dam K; Clodi M
    World J Surg; 1994; 18(4):583-7. PubMed ID: 7725748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
    Naidu R; Wahab NA; Yadav M; Kutty MK
    Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis.
    Shi Y; Zou M; Farid NR
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):269-74. PubMed ID: 8222289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferating cell nuclear antigen (PCNA) in medullary thyroid carcinoma.
    Skopelitou A; Korkolopoulou P; Papanikolaou A; Hadjiyannakis M
    J Cancer Res Clin Oncol; 1993; 119(7):379-81. PubMed ID: 8098331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.
    Wang DG; Liu WH; Johnston CF; Sloan JM; Buchanan KD
    Am J Pathol; 1998 Jun; 152(6):1407-13. PubMed ID: 9626044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta 1 induces growth inhibition of a human medullary thyroid carcinoma cell line despite an increase in steady state c-myc messenger ribonucleic acid levels.
    Khosla S; Oursler MJ; Schroeder MJ; Eberhardt NL
    Endocrinology; 1994 Nov; 135(5):1887-93. PubMed ID: 7956909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors of survival in medullary cancers of the thyroid. Apropos of 51 cases. Clinical, biochemical and immunocytochemical study].
    Goudet P; Rogissart F; Petit JM; Vaillant G; Durnerin I; Fraisse J; Justrabo E; Verges B; Cougard P
    Ann Chir; 1996; 50(1):23-9. PubMed ID: 8734273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A; Margaria E; Chiusa L
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of c-myc oncogene in human esophageal carcinoma: immunohistochemistry, in situ hybridization and northern and Southern blot studies.
    Miyazaki S; Sasno H; Shiga K; Sawai T; Nishihira T; Okamoto H; Mori S
    Anticancer Res; 1992; 12(5):1747-55. PubMed ID: 1444241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
    Pennelli G; Galuppini F; Barollo S; Cavedon E; Bertazza L; Fassan M; Guzzardo V; Pelizzo MR; Rugge M; Mian C
    Hum Pathol; 2015 Jan; 46(1):50-7. PubMed ID: 25316501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression.
    Kawate S; Fukusato T; Ohwada S; Watanuki A; Morishita Y
    Oncology; 1999; 57(2):157-63. PubMed ID: 10461064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients.
    Scopsi L; Sampietro G; Boracchi P; Del Bo R; Gullo M; Placucci M; Pilotti S
    Cancer; 1996 Nov; 78(10):2173-83. PubMed ID: 8918412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative activity in C-cell hyperplasia and medullary thyroid carcinoma. Evaluation by PCNA immunohistochemistry and AgNORs staining.
    Matias-Guiu X; Peiro G; Esquius J; Oliva E; Cabezas R; Colomer A; Prat J
    Pathol Res Pract; 1995 Feb; 191(1):42-7. PubMed ID: 7651932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
    Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
    Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.